Last week, Biosimilars Canada, a trade organization representing Canada’s biosimilar developers including Sandoz, Mylan, and Fresenius Kabi, among others, announced that it had chosen Innomar Strategies to be the preferred provider for the Biosimilars Canada Patient Support Program platform.
Last week, Biosimilars Canada, a trade organization representing Canada’s biosimilar developers including Sandoz, Mylan, and Fresenius Kabi, among others, announced that it had chosen Innomar Strategies to be the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform.
Innomar Strategies, an AmerisourceBergen company, focuses on providing a balance between patient care and market access as it “continues to deliver innovative solutions to specialty manufacturers to improve product access, increase supply chain efficiency, and ultimately enhance patient care.”
The PSP platform will provide patient support services for members of Biosimilars Canada members that can be customized to meet the individual needs of the therapy, the biosimilar sponsor, and payer.
“The Biosimilars Canada PSP platform will be an important solution in ensuring biosimilar sponsors can provide high quality patient support services required by payers, physicians, and patients while providing value to the Canadian healthcare system,” said Jim Keon, president of Biosimilars Canada, in a statement.
To date, Health Canada has approved 12 biosimilar medicines now available on the market, though uptake has been somewhat slow, similar to what is seen in the US marketplace. Biosimilars Canada has surmised that the use of biosimilar medicines will increase more rapidly in 2019 as more biosimilars are launched, and as coverage policies evolve to include more biosimilar medications.
“The availability of biosimilar medicines in Canada helps to enhance competition, improve access to biologic medicines, and contribute to the financial sustainability of healthcare systems,” said Michel Robidoux, chair of Biosimilars Canada and president and general manager of Sandoz Canada.
According to Biosimilars Canada, the patient support platform will be launched in 2019.
“As more biosimilars come into the market, patients will need services built around these products to support them with their illness. By utilizing a centralized Patient Support Program model, healthcare providers, manufacturers and patients will experience efficiencies, while still having a best-in-class experience,” said Kevin West, vice president of Innomar Strategies.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.